Angelini announces close of acquisition of two Sanofi consumer healthcare (CHC) products in Germany and Austria for a total of € 47 M

Rome, 29 August 2019

The acquired products include BoxaGrippal® (ibuprofen/pseudoephedrine) a Pharmacy-Only OTC brand that provides effective temporary relief from a range of Common Cold & Flu symptoms, and Heumann a well-established Pharmacy-Only OTC herbal medicinal group of teas for the treatment of diverse conditions, including mild bladder and kidney sicknesses, cough and stomach-bowel ache.

Boxagrippal® was launched by Boehringer Ingelheim in 2013 and today top ranks in its category (#4 in Germany and #3 in Austria).

Heumann Teas have a strong heritage of more than 60 years in herbal medicinal preparations.

Those acquired products support Angelini Pharma reinforcing both its OTC business and consolidating its presence in Germany and Austria. Boxagrippal® and Heumann Teas will add to the main brand Tantum®, successfully marketed in the two above mentioned countries since many years.

Angelini S.p.a.
Viale Amelia 70, 00181 Roma
P.IVA 01258691003 e C.F. Numero di iscrizione registro imprese: 03907010585
Ufficio del registro delle imprese: Roma
Capitale: € 165.000.000 I.V.

© Angelini S.p.a. - Tutti i diritti riservati